Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Neonatol. 2012 Oct;1(4):171-5. doi: 10.4103/2249-4847.105958.

Is sildenafil an effective therapy in the management of persistent pulmonary hypertension?

Author information

1
Department of Pediatric, University Hospital Sharjah, Sharjah, United Arab Emirates.

Abstract

Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening neonatal pathology resulting from poor hemodynamic and respiratory transition to extra uterine life. Inhaled nitric oxide (iNO) is a current, commonly used treatment of PPHN. However, iNO is not available therapy in many developing countries and around 50% of infants with PPHN do not respond to iNO therapy. Sildenafil is a phosphodiesterase inhibitor type 5 (PDE5) that has been shown to selectively reduce pulmonary vascular resistance in both animal models and adult humans. Recent studies have found that in PPHN, administration of Sildenafil was associated with a significant increase in the oxygenation and a reduction in mortality with no clinically important side effects.

KEYWORDS:

Neonate; persistent pulmonary hypertension; sildenafil

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Support Center